Wolfe Research analyst Mike Polark upgraded Sotera Health to Outperform from Peer Perform with a $25 price target. The analyst is updating his model to include the announces settlement of Ethylene Oxide litigation in Illinois with the add-in of expected borrowing to cover the proposed settlement. Polark notes that he sees a lot of room for Sotera Health multiple to continue recovering as the proposed settlement progresses to final and as the company’s fundamental merits – namely, substantial moat, real pricing power, favorable industry structure, and long-duration contracts – return.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SHC:
- Sotera Health upgraded to Outperform from Peer Perform at Wolfe Research
- Sotera Health double-upgraded to Overweight from Underweight at Barclays
- Sotera Health ‘to rock’ with ‘massive overhang’ removed, says Wolfe Research
- Here’s What Caused Sotera Health’s (NASDAQ:SHC) Stunning Rally
- Sotera Health Announces Settlement of Ethylene Oxide Litigation in Illinois